Your browser doesn't support javascript.
loading
Evaluation of the Cephalosporin Antimicrobial Drug Administration Program Using Monte Carlo Simulation / 中国药学杂志
Chinese Pharmaceutical Journal ; (24): 725-728, 2018.
Article en Zh | WPRIM | ID: wpr-858351
Biblioteca responsable: WPRO
ABSTRACT
OBJECTIVE: To evaluate and optimize the treatment regimen of cephalosporins based on Monte Carlo simulation and the pharmacokinetics /pharmacodynamics (PK/PD) model. METHODS: The treatment regimens of cefradine, cefuroxime, ceftriaxone and cefepime are 0.75 g qid, 1 g qid, 2 g bid and 2 g tid. And a total of 903 strains from eight species were collected. The minimum inhibitory concentration (MIC) was measured by trace broth dilution method. Monte Carlo simulation was used to simulate the regimens against Escherichia coli, Bacillus, Klebsiella pneumoniae, Acinetobacter baumannii, Citrobacter, Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa. Then, the cumulative fraction of response (CFR) was calculated. RESULTS: Cefhradine and cefuroximes' rates of resistance were higher (47.31% - 100%), the cumulative reaction scores(CFR) were all less than 90%. Cefuroxime has desirable regimen for Escherichia coli, Klebsiella pneumoniae, Citrobacter and Streptococcus pneumoniae. Cefepime has at least one dose regimen's CFR for more than 90%, and cephalosporins is consistent with time-dependent drug characteristics. CONCLUSION: For the treatment of infectious diseases, the choice of cephalosporins should be used to follow the principles of antibiotics. Target therapy should be used to test the pathogen susceptibility test, according to the value of MIC to simulate the corresponding dosing regimen, to achieve individualized administration.
Palabras clave
Texto completo: 1 Índice: WPRIM Tipo de estudio: Evaluation_studies / Prognostic_studies Idioma: Zh Revista: Chinese Pharmaceutical Journal Año: 2018 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Tipo de estudio: Evaluation_studies / Prognostic_studies Idioma: Zh Revista: Chinese Pharmaceutical Journal Año: 2018 Tipo del documento: Article